HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wellness Industry News: MacKay Leaving CRN; Another Life-Line Recall, Ginkgo Bioworks' Second Startup, More

Executive Summary

Duffy MacKay is leaving CRN and Andrew Shao will return for an interim period; McDaniel Life-Line recalls all lots of its Life-Line Water due to contamination; Harvest One acquires LivRelief supplement firm; and Gingko Bioworks' second startup funded $90m.

You may also be interested in...



Taisho Wraps BMS Consumer Health Acquisition; iAnthus Nabs CBD For Life; Health & Wellness M&A In Brief

Bristol-Myers Squibb is free to focus on drug development for patients facing serious diseases, with the divestment of its UPSA consumer health business to Taisho now complete. Separately, Harvest One Cannabis and iAnthus Capital Holdings build their capabilities to meet soaring demand for CBD and other cannabis-derived health, wellness and beauty products.

FDA Warns On Releasing 'At Risk' Drugs, Making Supplements In Kitchen, Claims For Diatomaceous Earth

Kingston Pharma needs to review; McDaniel Life-Line risks contamination; Earthworks multi-channel marketing; ActiveHerb TCM Lines noncompliant; AMMD skips finished product tests; and PRL warned on GMPs, claims.

Legalizing Marijuana Would Calm CBD Regulatory Storm – CV Sciences' MacKay

As FDA moves slow on allowing CBD as a dietary ingredient, a marijuana reform law is a near-term possibility and would cause a “nuclear shift” about cannabis regulation and sway agency's decision, says cannabidiol firm CV Sciences executive.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS148610

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel